156072-84-3

Basic information

• Product Name: 5-Chloro-3-methylpyridine-2-carbonitrile
• Synonyms: 5-Chloro-3-methylpyridine-2-carbonitrile;5-Chloro-2-cyano-3-methylpyridine, 5-Chloro-3-methylpicolinonitrile;5-Chloro-3-Methylpicolinonitrile
• CAS NO: 156072-84-3
• Molecular Formula: C₇H₅ClN₂
• Molecular Weight: 153
• Mol File: 156072-84-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Chloro-3-methylpyridine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-3-methylpyridine-2-carbonitrile(156072-84-3)
• EPA Substance Registry System: 5-Chloro-3-methylpyridine-2-carbonitrile(156072-84-3)

Safety Data

• Hazardous Substances Data: 156072-84-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-Chloro-3-methylpyridine-2-carbonitrile is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a valuable building block for the development of new drugs and pesticides.
Used in Organic Synthesis:
5-Chloro-3-methylpyridine-2-carbonitrile is used as a building block in organic synthesis, particularly in the production of heterocyclic compounds. Its versatile reactivity and functional group compatibility allow for the creation of a wide range of complex organic molecules.
Used in Materials Science:
5-Chloro-3-methylpyridine-2-carbonitrile has potential applications in the field of materials science. Its unique properties may contribute to the development of new materials with specific characteristics, such as improved stability or reactivity.
Used as a Reagent in Chemical Research:
5-Chloro-3-methylpyridine-2-carbonitrile is also used as a reagent in chemical research. Its diverse synthetic applications make it a valuable tool for scientists exploring new chemical reactions and pathways.

Upstream product

• 7758-89-6 copper(I) chloride 
• 252056-70-5 5-amino-3-methylpyridine-2-carbonitrile 
• 557-21-1 zinc(II) cyanide 
• 52409-22-0 tris-(dibenzylideneacetone)dipalladium⁽⁰⁾ 
• 65550-77-8 2-bromine-3-methyl-5-chloropyridine 

Downstream Products

• 1624603-92-4 N-(3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-chloro-3-methylpyridine-2-carbothioamide 
• 1624603-18-4 N-(3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-chloro-3-methyl-2-pyridinecarboxamide 
• 886365-46-4 5-chloro-3-methylpyridine-2-carboxylic acid 
• 1624604-70-1 N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4,5-difluorophenyl)-5-chloro-3-methylpicolinamide 

Relevant articles and documents

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.